Navigation Links
Lymphoblastic in Medical News

Micromet, Inc. Reports Second Quarter 2009 Financial Results

... of blinatumomab phase 2 data in acute lymphoblastic leukemia (ALL) at the 14(th) Congress of the ... forward to initiating a pivotal trial in acute lymphoblastic leukemia in 2010," stated Christian Itin, Ph.D., ... trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial ...

2009 recipient of minority scholar award begins clinical research on leukemia

... research into the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) this month. The award, the ... the Molecular Pathogenesis of T-Cell Acute lymphoblastic Leukemia Using Zebrafish Genetics and Small ... the molecular pathogenesis of T-cell acute lymphoblastic leukemia. Specifically, Dr. Gutierrez is ...

For Kids With Leukemia, Radiation May Be Safe to Skip

... for most children with newly diagnosed acute lymphoblastic leukemia, new research has found. In fact, ... cure up to 90 percent of all children with acute lymphoblastic leukemia without the use of cranial irradiation," ... Memphis, Tenn. "Survivors of childhood acute lymphoblastic leukemia can now enjoy excellent quality of life, ...

New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease

... a fundamental role in the prognosis of acute lymphoblastic leukemia as well as in response to treatment, ... - 179 children and 174 adults - with acute lymphoblastic leukaemia). The results open up new therapeutic ... of results. It is notable that acute lymphoblastic leukaemia is the most common oncological illness ...

In Kids, Genes May Affect Leukemia Treatment

... affect the way children respond to treatment for lymphoblastic leukemia, researchers report. Although about ... studied genetic variations in 487 children with lymphoblastic leukemia. Their goal was to find evidence of ... that almost 20 percent of children treated for lymphoblastic leukemia suffer cognitive damage from ...

Gene Governs Response to Leukemia Chemotherapy

... Acute lymphoblastic leukemia is most common pediatric cancer ... leukemia cells predicts which children with acute lymphoblastic leukemia are more likely to relapse. The ... subsets of patients. "The treatment of acute lymphoblastic leukemia (ALL) is really one of the success ...

Novel treatments show improvements in survival and response rates for leukemia and lymphoma

... early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood ... One-Third of All Relapses in Childhood Acute lymphoblastic Leukemia: Results of an International Randomized ... of event-free survival in children with acute lymphoblastic leukemia. Dexamethasone was associated with a ...

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma

... early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood ... One-Third of All Relapses in Childhood Acute lymphoblastic Leukemia: Results of an International Randomized ... of event-free survival in children with acute lymphoblastic leukemia. Dexamethasone was associated with a ...

St. Jude Discovery Offers New Avenues to Understanding an Aggressive Form of Leukemia

... mutations can cause an aggressive form of acute lymphoblastic leukemia could lead to new ... of an aggressive and often-fatal form of acute lymphoblastic leukemia (ALL). These defects, known as ... system. "The vast majority of pediatric acute lymphoblastic leukemias are of B-cell lineage," Downing ...

Stem cells give clues to understanding cancer and make breakthrough in childhood leukaemia

... the most common form of childhood cancer, acute lymphoblastic leukaemia (ALL). The research should lead to less ... presented findings of his research on acute lymphoblastic leukaemia (ALL), which has now been published in ... we can now test whether the treatment of acute lymphoblastic leukaemia in children can be correlated with ...

More>>

Lymphoblastic in Medical Technology

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

... Germany, showing a high response rate in acute lymphoblastic leukemia (ALL) patients with minimal residual ... (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II ... trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial ...

St. Jude Finds More Than 100 Gene Variations Linked With Response to Leukemia Treatment

... drugs in the body for children with acute lymphoblastic leukemia MEMPHIS, Tenn., Jan. 27 ... (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic ... array of antileukemic medications used to treat lymphoblastic leukemia. Pharmacokinetics comprises the various ...

Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation

... chemotherapy can improve cure rate and avoid the use of radiation in acute lymphoblastic leukemia treatment MEMPHIS, Tenn., June 24 /PRNewswire-USNewswire/ -- Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized ...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

... Blinatumomab -- a rapid path to market has been identified for Acute lymphoblastic Leukemia (ALL) with a registration trial planned to begin in 2010. Dose ... It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with ...

Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions

... Nurses and Pharmacists VOORHEES, N.J., April 22 /PRNewswire/ -- Acute lymphoblastic leukemia (ALL) is a complex heterogeneous disease which, despite ... education online activity and podcast titled Expert Insights in Acute lymphoblastic Leukemia: Current Challenges and Future Directions . This activity, which ...

Gene Abnormality Found to Predict Childhood Leukemia Relapse

... in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL). Although the researchers caution that further research is ... the Children's Oncology Group. Deletion of IKZF1 and Prognosis in Acute lymphoblastic Leukemia. NEJM . Vol. 360, No. 5. St. Jude Children's Research ...

Micromet Key Events for 2009

... 4 to 7, 2009: Update on phase 2 clinical trial with blinatumomab in acute lymphoblastic leukemia (ALL) patients at the 14th Congress of the European Hematology ... It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with ...

St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse

... New study finds the majority of acute lymphoblastic leukemia relapse cases arise from a cell already present at the time of ... distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse. The finding offers a pathway to ...

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

... antibody blinatumomab (MT103/MEDI-538) in patients with adult acute lymphoblastic leukemia (ALL). Blinatumomab is a T cell engaging antibody targeting the ... is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

More>>

Lymphoblastic in Medical Dictionary

Acute lymphocytic leukemia

... the body? Acute lymphocytic leukemia ( acute lymphoblastic leukemia , ALL) accounts for about 3,800 new ... the blood and bone marrow . Also called acute lymphoblastic leukemia . They include acute lymphocytic ... percent of children with the disease . Acute lymphoblastic leukemia is also called acute lymphocytic ...

Acute lymphoblastic

... Acute lymphoblastic leukemia : An acute (sudden onset), rapidly ... destined to become lymphocyte s. Adult Acute lymphoblastic Leukemia in Remission Current approaches to post remission therapy for adult acute lymphoblastic leukemia (ALL) include short-term, ... You ...

Acute myelogenous leukemia

... ( Acute Nonlymphocytic Leukemia ) Acute lymphoblastic Leukemia Acute Nonlymphocytic Leukemia Agranulocytosis ALL ( Acute lymphoblastic Leukemia ) AML ( Acute Nonlymphocytic ... The TdT stain differentiates between acute lymphoblastic leukemia (cells stain positive) and acute ...

Acute

... angle-closure glaucoma is caused by a rapid or sudden increase in pressure inside the eye , called intra ocular pressure (IOP). Acute lymphoblastic leukemia : An acute (sudden onset), rapidly progressing form of leukemia that is characterized by the presence in the blood and bone marrow ...

Acute HIV infection

... exposure to HIV . Acute HIV infection Acute idiopathic poly neuritis Acute illness Acute kidney failure Acute leukemia Acute lymphoblastic leukemia Acute lymphocytic leukemia Acute membranous gingivitis Acute mountain sickness (AMS) Acute myelogenous leukemia ... ...

Agranulocytosis

... a condition in which there is an insufficient number of white blood cells called neutrophil s or granulocyte s. Agranulocytosis ALL ( Acute lymphoblastic Leukemia ) AML ( Acute Nonlymphocytic Leukemia ) Anemia Aplastic Anemia A PTT ( Partial Thromboplastin Time) Auto immune Thrombocytopenia ...

Cml

... stages of CML , most people have no symptoms of cancer . CML is less common in children than other types of leukemia , including acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) What causes leukemia in children? In CML , if bone marrow transplant ation is ...

Cranium

... can be applied as a moldable putty or injectable paste. : Basal cell carcinoma in a girl after cobalt irradiation to the cranium for acute lymphoblastic leukemia : case report and literature review. Pediatr Dermatol 13 (1): 54-7, 1996 Jan-Feb. [PUBMED Abstract] ... ...

Graft Versus Host Disease

... tissue . : Total body irradiation correlates with chronic graft versus host disease and affects prognosis of patients with acute lymphoblastic leukemia receiving an HLA identical allogeneic bone marrow transplant . ...

Testicular biopsy

... Trigg ME, Stein herz PG, Chappell R, et al.: Early testicular biopsy in males with acute lymphoblastic leukemia : lack of impact on subsequent event-free survival. J Pediatr Hematol Oncol 22 (1): 27-33, 2000 Jan-Feb. [PUBMED Abstract] ... If you ...

More>>

Lymphoblastic in Biological News

Comprehensive look at rare leukemia finds relatively few genetic changes launch disease

... mutations involve a single chemical change in the molecular building blocks of DNA. The data demonstrated that, in contrast to pediatric acute lymphoblastic leukemia (ALL), AML is characterized by a very low burden of mutations. The researchers found slightly more than two CNAs per AML patient, and less ...

St. Jude identifies genomic causes of a certain type of leukemia relapse

... Scientists at St. Jude Children's Research Hospital have identified distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse. The finding offers a pathway to designing treatments for ALL relapse in children and, ultimately, in adults. ...

Lab study shows methadone breaks resistance in untreatable forms of leukemia

... culture because this cancer also expresses the opioid receptor. Theirs is the first study to look at use of the agent in leukemia, specifically in lymphoblastic leukemia T-cell lines and human myeloid leukemia cell lines. They found that methadone was as effective as standard chemotherapies and radiation ...

Ireland Cancer Center researchers advance stem cell gene therapy

... Group (ECOG) presented data that show that Imatninib (Gleevec) does not change outcomes on patients with Philadelphia Chromosome Positive Acute lymphoblastic Leukemia. Dr. Lazarus presented an assessment of data over 30 years regarding acute leukemia and its management. He found that all avenues ...

Daisies lead scientists down path to new leukemia drug

... end of 2007. Investigators expect to initially enroll about a dozen adult volunteers whove been diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or other types of blood or lymph cancers, Jordan said. Under development is dimethylamino-parthenolide (DMAPT), a form of ...

St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia

... has revolutionized the treatment of chronic myelogenous leukemia, (CML) is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL). Targeted therapy drugs are designed to block the activity of a specific molecule, a strategy aimed at making treatments more ...

Retinol for combating leukemia cells

... of retinamide in certain types of leukemia - lymphoblastic leukemias. Nowadays, samples from the Hospital de ... in order to get these types of leukemia cells. lymphoblastic leukemias are, as their name indicates, a type of ... retinamide has great potential to eliminate the lymphoblastic cells without affecting healthy lymphocytes nor ...

Research shows cord blood comparable to matched bone marrow

... Blood Program at the New York Blood Center. The analysis included transplant outcomes in 785 children younger than 16 who had the diagnosis of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). ...

Major gene study uncovers secrets of leukemia

... at St. Jude Children's Research Hospital have discovered previously unsuspected mutations that contribute to the formation of pediatric acute lymphoblastic leukemia (ALL), the most common cancer in children. The discovery not only suggests novel methods for treating pediatric ALL, but also provides a ...

Knocking out survival protein could aid leukemia treatment

... with several existing drugs might also offer an effective one-two punch against drug-resistant forms of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). The two forms of cancer kill about 20,500 Americans yearly. The survival protein is called Mcl1. It usually helps keep normal ...

More>>

Lymphoblastic in Biological Technology

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... for BiTE antibody blinatumomab (MT103) for acute lymphoblastic leukemia (ALL). Blinatumomab is a novel ... Germany, showing an 81% response rate in acute lymphoblastic leukemia (ALL) patients with minimal residual ... disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

... trial with blinatumomab in patients with acute lymphoblastic leukemia (ALL) were chosen for an oral ... disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing phase II ... trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the ...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

... for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the ... of blinatumomab in adult patients with acute lymphoblastic leukemia. In September, Micromet ... phase 2 clinical trial with blinatumomab in acute lymphoblastic leukemia (ALL) patients at the 14th Congress of ...

Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias

... a Phase 2 Clinical Trial in B-Precursor Acute lymphoblastic Leukemia Show that Blinatumomab is Able to ... (MT103/MEDI-538) in patients with acute lymphoblastic leukemia (ALL). Blinatumomab is a novel ... German Multicenter Study Group for Adult Acute lymphoblastic Leukemia (GMALL). "The ability to convert a ...

Micromet, Inc. Reports Third Quarter 2008 Financial Results

... ongoing phase 2 clinical trial of blinatumomab in patients with acute lymphoblastic leukemia. Conference Call and Audio Webcast Today, November 6, 2008, at ... It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with ...

Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results

... to treat. In Europe, Micromet has initiated a phase 2 study in acute lymphoblastic leukemia, one of the most aggressive blood cancers. -- Micromet has ... is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients ...

Micromet Closes $80.5 Million Public Offering of Common Stock

... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Micromet Announces Pricing of Public Offering of Common Stock

... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Micromet Announces Public Offering of Common Stock

... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...
Lymphoblastic in Biological Products

Terminal deoxynucleotidyl transferase (TdT) Immunofluorescence Assay Kit from AbD Serotec

Description:... subpopulation of bone marrow prelymphocytes. Elevated levels of the enzyme and increased numbers of TdT cells are found to be associated with some lymphoblastic leukaemias and lymphomas. Presence of TdT thus provides a useful adjunct in the differentiation of leukaemias and also in monitoring response to ...
Company:AbD Serotec

MOLT - 4 cell line slides ( human: T lymphoblast; acute lymphoblastic leukemia ) from GeneTex

Description: Human MOLT-4 cells were cultured in RPMI 1640 with 2 mM L-glutamine and harvested at the log phase of growth. In order to keep the antigens in their native forms, cells were fixed in acetone-methanol. The cells are arrayed on a 12-well (5 mm) adhesive coated slide, with each wells surface ...
Company:GeneTex
Other Contents
(Date:7/11/2014)... (PRWEB) July 11, 2014 Utilizing the ... own, Dr. William Koenig, has topped a record number ... he has performed over 400 successful procedures without the ... Koenig is well known across the country for his ... safety record has long been the foundation for numerous ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- In people with ... are similar to that seen in drug addicts as ... are clear differences in brain activity between patients who ... mirror those of drug addicts," study author Dr. Valerie ... in a university news release. Voon,s research involved ...
(Date:7/11/2014)... -- U.S. health officials have concluded that it,s highly ... during a safety mishap last month. But, the ... announced a moratorium on the transfer of any dangerous ... a report issued Friday, the CDC outlined several measures ... incident doesn,t occur again. Last month, as many as ...
(Date:7/11/2014)... 2014 The report “Probiotics Market ... Animal Feed), Applications (Regular, Therapeutic, Preventive Health Care) ... & Forecasts to 2019 ” defines and segments ... forecasting of the market value of probiotic products ... and restraining factors for the global market with ...
(Date:7/11/2014)... 11, 2014 According to a new ... Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, ... Automotive & Transportation, Agriculture) & Geography - Global Trends ... Internet of Things market was worth $1029.5 Billion in ... 2020, at an estimated CAGR of 4.08% from 2014 ...
Breaking Medicine News(10 mins):Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... increased risk of kidney injury related to the use ... mass of HES molecules, according to a report in ... International Anesthesia Research Society (IARS). , The "total mass ... on cultured human renal proximal tubule cells (PTCs), concludes ... of University Hospital Wrzburg, Austria. Other factorssuch as ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
Other TagsOther Tags